Abstract: The invention provides methods and kits for the analysis of extracellular vesicle-derived biomarkers obtained from dried body fluid samples; including but not limited to blood spots extracted onto or into absorptive surfaces for analysis of extracellular vesicles for disease diagnosis, staging, monitoring and selection and efficacy of therapeutics.

Abstract: A column tube holder includes: a first side rail extending vertically; a second side rail extending vertically; a first shelf extending horizontally between the first side rail and the second side rail; a second shelf extending horizontally between the first side rail and the second side rail, the second shelf disposed below the first shelf; and a third shelf extending horizontally between the first side rail and the second side rail, the third shelf disposed below the second shelf. The column tube holder is composed of a conductive material, an anti-static material, and/or a static dissipative material.

Abstract: The present disclosure in one aspect provides technologies for detection of esophageal cancer, e.g., early detection of esophageal cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to esophageal cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.

Abstract: The present disclosure in one aspect provides technologies for detection of prostate cancer, e.g., early detection of prostate cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to prostate cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.

Abstract: The present disclosure in one aspect provides technologies for detection and/or screening of a plurality of cancers, e.g., early detection of various cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., but not limited to blood samples) that are associated with therapeutic response.

Abstract: The present disclosure in one aspect provides technologies for detection of breast cancer, e.g., early detection of breast cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to breast cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.

Abstract: The present disclosure in one aspect provides technologies for detection of pancreatic cancer, e.g., early detection of pancreatic cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to pancreatic cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.

Abstract: The present disclosure in one aspect provides technologies for detection of colorectal cancer, e.g., early detection of colorectal cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to colorectal cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.

Abstract: The present disclosure in one aspect provides technologies for detection of lung cancer, e.g, early detection of lung cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to lung cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g, by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.

Abstract: A column tube holder includes: a first side rail extending vertically; a second side rail extending vertically; a first shelf extending horizontally between the first side rail and the second side rail; a second shelf extending horizontally between the first side rail and the second side rail, the second shelf disposed below the first shelf; and a third shelf extending horizontally between the first side rail and the second side rail, the third shelf disposed below the second shelf. The column tube holder is composed of a conductive material, an anti-static material, and/or a static dissipative material.

Abstract: A column tube holder includes: a first side rail extending vertically; a second side rail extending vertically; a first shelf extending horizontally between the first side rail and the second side rail; a second shelf extending horizontally between the first side rail and the second side rail, the second shelf disposed below the first shelf; and a third shelf extending horizontally between the first side rail and the second side rail, the third shelf disposed below the second shelf. The column tube holder is composed of a conductive material, an anti-static material, and/or a static dissipative material.

Abstract: The present disclosure in one aspect provides technologies for detection of ovarian cancer, e.g., early detection of ovarian cancer. In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to ovarian cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in woman’s blood samples that are associated with therapeutic response.

Abstract: A column tube holder includes: a first side rail extending vertically; a second side rail extending vertically; a first shelf extending horizontally between the first side rail and the second side rail; a second shelf extending horizontally between the first side rail and the second side rail, the second shelf disposed below the first shelf; and a third shelf extending horizontally between the first side rail and the second side rail, the third shelf disposed below the second shelf. The column tube holder is composed of a conductive material, an anti-static material, and/or a static dissipative material.

Abstract: The present disclosure provides technologies for target entity detection. One aspect of the present disclosure provides technologies for detection (e.g., early detection) of a disease, disorder, or condition (e.g., cancer). In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject in need thereof, e.g., a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.

Abstract: The present disclosure provides technologies for target entity detection. One aspect of the present disclosure provides technologies for detection (e.g., early detection) of a disease, disorder, or condition (e.g., cancer). In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject in need thereof, e.g., a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.

Abstract: The present disclosure provides technologies for target entity detection. One aspect of the present disclosure provides technologies for detection (e.g., early detection) of a disease, disorder, or condition (e.g., cancer). In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject in need thereof, e.g., a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.

Abstract: The present disclosure provides technologies for target entity detection. One aspect of the present disclosure provides technologies for detection (e.g., early detection) of a disease, disorder, or condition (e.g., cancer). In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject in need thereof, e.g., a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.